| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 52.49 | 1029 |
| Intrinsic value (DCF) | 1297.14 | 27795 |
| Graham-Dodd Method | n/a | |
| Graham Formula | 30.17 | 549 |
Coya Therapeutics, Inc. (NASDAQ: COYA) is a clinical-stage biotechnology company pioneering innovative therapies that modulate regulatory T cells (Tregs) to treat neurodegenerative, autoimmune, and metabolic diseases. Headquartered in Houston, Texas, Coya leverages proprietary Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy to develop groundbreaking treatments. Its lead candidate, COYA 101, has completed Phase 2a trials for Amyotrophic Lateral Sclerosis (ALS), while COYA 301 and COYA 302 target Frontotemporal Dementia and other conditions through IND-enabling studies. The company also explores preclinical-stage allogeneic exosome therapies (COYA 201) and antigen-directed exosome candidates (COYA 206). Operating in the high-growth biotechnology sector, Coya stands out for its focus on Treg modulation—a promising approach in immunotherapy. With a market cap of ~$98.7 million and a robust pipeline, Coya is positioned to address unmet medical needs in neurodegenerative and autoimmune diseases, attracting investor interest in cutting-edge biotech innovation.
Coya Therapeutics presents a high-risk, high-reward opportunity for investors focused on clinical-stage biotech. The company’s novel Treg-modulating platform addresses large markets (ALS, dementia, autoimmune diseases), but its near-term viability hinges on clinical success and funding. With no approved products, $14.9M net losses (FY 2024), and negative operating cash flow (-$10.3M), dilution risk is elevated. However, $38.3M in cash reserves provides runway for pipeline advancement. The low beta (0.495) suggests limited correlation to broader markets, typical of early-stage biotech. Key catalysts include Phase 2b data for COYA 101 and IND submissions for COYA 301/302. Investors should weigh the potential of Treg therapies against the sector’s high failure rates and capital-intensive R&D.
Coya Therapeutics competes in the niche but rapidly evolving Treg therapy space, differentiating itself through a multi-modal platform (biologics, exosomes, cell therapy). Its focus on neurodegenerative diseases (e.g., ALS, Frontotemporal Dementia) offers a strategic edge, as these conditions lack disease-modifying treatments. Competitors like Sangamo Therapeutics (SGMO) and Kyverna Therapeutics (KYTX) target autoimmune diseases with Treg approaches but lack Coya’s neurodegenerative focus. Coya’s autologous COYA 101 could face scalability challenges compared to allogeneic therapies but may offer superior safety. The exosome pipeline (COYA 201/206) positions Coya against Evox Therapeutics (private) and Codiak BioSciences (former CDAK), though earlier-stage development increases risk. Coya’s capital efficiency ($38.3M cash, no debt) is a strength, but larger peers like Regeneron (REGN) could outpace it with broader resources. The company’s IP around Treg enhancement and exosome engineering is critical to maintaining competitiveness in this emerging field.